Latest Antiviral drug Stories
PALO ALTO, Calif., Dec, 22, 2014 /PRNewswire/ -- Eiger BioPharmaceuticals Incorporated announced the positive results of a Phase 2a study of lonafarnib in patients with chronic hepatitis delta
PARIS, December 1, 2014 /PRNewswire/ -- ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced
- Results demonstrated high response rates in adult chronic hepatitis C genotype 4 patients without cirrhosis BOSTON, Nov.
Presented: Monday, November 10, 2014, 3:00 pm Eastern - Hynes Convention Center, Boston, MA BOSTON, Nov.
An experimental drug currently being trialed for influenza and Ebola viruses could have a new target: norovirus, often known as the winter vomiting virus.
Data from 25 accepted abstracts include results from: NORTH CHICAGO, Ill., Oct.
MILFORD, Mass., Sept.
Complimentary Hayes, Inc.
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...
Human rhinoviruses are the most common viral ineffective agents in humans and are the cause of the common cold. The infection proliferates between 33-35 Â°C causing most reproduction to occur in the nose. It is a species in the genus Enterovirus of the Picornaviridae family of viruses. There are 99 recognized types of Human Rhinoviruses that are differentiated by their surface proteins. They are amongst the smallest viruses and lytic in nature. They travel via aerosols of respiratory...
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.